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Abstract 
 
Osteosarcoma (OS) and prostate cancer are two types of cancer that both affect bone because 
osteosarcoma itself develops in bone and prostate cancer cells mainly metastasize to bone and 
cause significant mortality and morbidity in men with advanced disease. 
Today, many therapeutical options are available to treat OS and prostate cancer. 
Current optimal treatment for osteosarcoma consists of multi-agent chemotherapy and 
aggressive surgical resection. Suramin, a polysulfonated naphthylurea compound, has been 
widely used for antitrypanosomal treatment. Its anticancer activity was later identified and 
suramin has been introduced into clinical trials for various forms of cancer.  
Lysyl Oxidase (LOX) is the key enzyme that controls collagen and elastin maturation 
by catalyzing inter-and intamolecular cross-link formation. In the last few years it was found 
out that the LOX propeptide, which is released during extracellular proteolytic processing of 
pro-lysyl oxidase possesses anti-cancer activity. 
It was shown that suramin drastically upregulated LOX expression and induced phenotype 
reversion of transformed NIH3T3 cells but today few data exist that show effects of suramin 
in osteosarcoma cells. 
The clinical manifestation of prostate cancer varies from indolent tumours, requiring little or 
no treatment to aggressive cancers which require radical therapies. Today, metastatic prostate 
cancer is generally treated by hormone therapy. 
Epigenetic events are defined as alterations in gene expression without changes in the 
DNA coding sequence. DNA methylation by DNA methyltransferases (DNMT´s) and histone 
modification are two mechanisms that are integral to epigenetic transcriptional control. 
Promoter hypermethylation of cancer-related genes is found in nearly all tumours, including 
prostate cancers. It has been shown that the combination of DNMT inhibitors induces 
apoptosis, differentiation and/or cell growth arrest in different cancer cell lines. In prostate 
cancer, a number of studies have reported reductions in cell proliferation and apoptosis in cell 
lines treated with histone-deacetylase (HDAC) inhibitors alone but little is known about the 
effects of combination therapy. 
Aim of this thesis was to study the effects of suramin, the DNMT inhibitor 5-AZAC 
and the HDAC inhibitor valproate on different osteoblast-associated tumour cell lines, taking 
into special consideration the effects on osteoblastic differentiation and LOX expression.  
 Human (MG-63 and U-2 OS) and rat (UMR-106) OS cell lines as well as human 
prostate metastatic cell lines (DU-145, PC-3 and LNCaP) were seeded and treated with or 
without suramin and HDAC and DNMT inhibitors, respectively. Thereafter the effects on cell 
multiplication and differentiation (alkaline-phosphatase activity and specific marker genes) 
and LOX were studied.  
 Suramin inhibited cell multiplication in all osteosarcoma cell lines tested and 
increased genes of the osteoblastic phenotype like alkaline phosphatase activity, OCN, OPN 
and COL1A1 in the human OS cell lines. Comparable effects were found with HDAC and 
DNMT inhibitors in human prostate cancer cells: attenuation of cell multiplication and 
increase of differentiation as indicated by upregulation of Runx2 by these drugs, at least in 
combined treatment. In all cell lines treated with suramin and HDAC and DNMT inhibitors 
LOX mRNA expression was increased significantly.    
Our results support recent data from the literature that LOX could be a regulator for reversion 
of tumourigenic phenotypes in OS and prostate cancer cells. 
 
 
Zusammenfassung 
 
Knochenkrebs (Osteosarkome) und Prostatakrebs sind Krebsarten, die beide den Knochen 
betreffen, da sich Osteosarkome im Knochen entwickeln und Prostatakrebszellen in den 
Knochen und in die Lymphknoten metastasieren können. Es stehen heute viele Möglichkeiten 
zur Behandlung der beiden Krebsarten zur Verfügung, wobei es bei Osteosarkomen zum 
Einsatz von Chemotherapie und der chirurgischen Entfernung der betroffenen Areale kommt.  
Suramin ist ein poly-sulfonierter Naphthylharnstoff, der bis heute bei der Behandlung von 
diversen parasitären Erkrakungen, wie der afrikanischen Schlafkrankheit, zum Einsatz 
kommt.  In Versuchen erkannte man, dass die Substanz eine anti-tumoröse Wirkung besitzt 
und Suramin wurde in klinische Studien bei verschiedensten Formen von Krebs 
aufgenommen. 
  Lysyl Oxidase (LOX) ist das Schlüssel-Enzym bei der Bildung von Kollagen und 
Elastin. In den letzten Jahren wurde bekannt, dass das Propeptid, welches bei der Spaltung der 
Pro-Lysyl-Oxidase entsteht, diverse Tumore in ihrem Wachstum hindert. Es wurde gezeigt, 
dass Suramin die LOX -Expression in Tumorzellen unterdrückt, aber nur wenige Daten 
existieren über die Wirkung der Substanz auf Osteosarkome. 
Die klinische Manifestation von Prostatakrebs variiert von nicht schmerzhaften Tumoren, die 
wenig oder keine Behandlung benötigen, bis hin zu agressiven Tumoren, die nur durch 
radikale Therapien bekämpft werden können.  
Epigenetische Veränderungen sind definiert als Veränderungen der Genexpression 
ohne Veränderungen der DNA- kodierenden Sequenzen. Promotor CpG Hypermethylierung 
und Histon-Hypoacetylierung, katalysiert von der DNA-Methyltransferase (DNMT) und 
Histon Deacetylase (HDAC), werden mit transkriptioneller Repression in einigen Krebsarten 
assoziiert. Studien berichten über einen Rückgang der Zell-Proliferation und der Apoptose in 
Prostatakrebs-Zellinien, die mit einem HDAC Inhibitor behandelt wurden, aber wenig ist 
bekannt über die Effekte einer Kombinationstherapie.  
Ziel dieser Arbeit war es nun, die Effekte von Suramin, dem DNMT Inhibitor 5-
AZAC und dem HDAC Inhibitor Valproat auf verschiedene Osteoblasten-assoziierte Tumor-
Zelllinien zu untersuchen. Ein besonderer Schwerpunkt lag dabei auf der Wirkung der 
Substanzen auf die osteoblastäre Differenzierung und die LOX-Expression.  
 Humane (MG-63 und U-2 OS) und tierische (UMR-106) Osteosarkom-Zelllinien, 
sowie humane, metastasierende Prostatakrebs-Zelllinien (DU-145, PC-3 und LNCaP) wurden 
ausgestreut und einerseits mit Suramin, andererseits mit HDAC bzw. DNMT Inhibitoren 
behandelt. Anschließend wurden die Effekte dieser Substanzen auf die Zellvermehrung und 
Differenzierung  (Messung der alkalischen Phosphatase und verschiedener Osteoblasten-
spezifischer Marker-Gene) und auf die LOX-Expression untersucht.  
 Suramin verhinderte die Zellvermehrung in allen untersuchten Osteosarkom-Zelllinien 
und erhöhte die Aktivität der alkalischen Phosphatase und die Expression von Osteoblast-
spezifischen Markern wie Osteocalcin, OPN  und COL1A1 in den humanen Zellen. 
Vergleichbare Effekte wurden auch in den mit HDAC und DNMT Inhibitoren behandelten 
Prostatakrebs-Zellen gefunden: Rückgang der Zellvermehrung und Anstieg der 
Differenzierung durch die Erhöhung von Runx2  – zumindest bei der Behandlung der Zellen 
mit beiden Substanzen. In allen untersuchten Zelllinien, die mit Suramin oder den HDAC 
bzw. DNMT Inhibitoren behandelt wurden kam es zu einem signifikanten Anstieg der LOX 
mRNA Expression. 
Unsere Ergebnisse bestätigen Daten aus der Literatur, wonach LOX eine Änderung des 
Phänotyps in Osteosarkomen und Prostatakrebszellen hervorrufen könnte. 
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1. Introduction 
 
1.1. Bone 
  
Bone is a specialized connective tissue that makes up, together with cartilage, the skeletal 
system. These tissues serve three functions: 1. mechanical, as support and site of muscle 
attachment for locomotion; 2. protective, for vital organs and bone marrow; and 3. metabolic, 
as a reserve of ions, especially calcium and phosphate, for the maintenance of serum 
homeostasis. Anatomically, two types of bones can be distinguished: flat bones (skull bones, 
scapula, mandible, and ileum) and long bones (tibia, femur, humerus) (Baron R, 2003). 
Flat bones undergo a process of intramembraneous ossification, whereas long bones increase 
in length via the endochondral ossification (Kronenberg HM, 2003). 
In intramembranous ossification, a group of mesenchymal cells, under the influence of local 
growth factors and under the regulation of the transcription factors Runx2 and Osterix (Baron 
R, 2003) condense and directly differentiate into preosteoblasts and then into bone-forming 
osteoblasts (Kronenberg HM, 2003). These cells synthesize a bone matrix where the collagen 
fibers are not preferentially oriented but appear as irregular bundles and where the osteocytes 
are large and extremely numerous. The calcification is delayed and does not proceed in an 
orderly fashion but in irregularly distributed patches. This type of bone is also called woven 
bone (Baron R, 2003). 
In endochondral ossification mesenchymal cells proliferate and differentiate into 
prechondroblasts and then into chondroblasts that form a cartilage template that is replaced by 
osteoblasts, forming mature bone (Kronenberg HM, 2003).  
External examination of a long bone shows two wider extremities, the epiphyses, a more or 
less cylindrical tube in the middle, the diaphysis, and a developmental zone between them, the 
metaphysis. In a growing long bone, the epiphysis and the metaphysis, which originate from 
two independent ossification centers, are separated by a layer of cartilage, the epiphyseal 
cartilage (also called growth plate). The external part of the bones is formed by a layer of 
calcified tissue, the cortex (compact bone), which, in the diaphysis, encloses the medullary 
cavity where the hematopoietic bone marrow is housed. Toward the metaphysis and the 
epiphysis, the cortex becomes progressively thinner, and the internal space is filled with a 
network of calcified trabeculae. This is the cancellous bone, also named trabecular bone. 
Cortical and trabecular bone are made of the same cells and the same matrix elements, but 
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there are structural and functional differences. The primary structural difference is 
quantitative: 80–90% of the volume of compact bone is calcified, whereas only 15–25% of 
the trabecular bone is calcified. The result is that 70–85% of the interface with soft tissues is 
at the endosteal bone surface, which leads to the functional difference: the cortical bone 
fulfills mainly a mechanical and protective function and the trabecular bone a metabolic 
function. Bone is formed by collagen fibers (type I, 90% of the total protein), and 
noncollagenous proteins. Spindle- or plate-shaped crystals of hydroxyapatite 
[3Ca3(PO4)2(OH)2] are found on the collagen fibers, within them, and in the ground 
substance. They tend to be oriented in the same direction as the collagen fibers.  
The preferential orientation of the collagen fibers alternates in adult bone from layer to layer, 
giving to this bone a typical lamellar structure. The activity of bone cells is performed along 
the surfaces of bone and it results in bone remodeling, a process involved in bone growth and 
turnover (Baron R, 2003). This remodeling requires the actions of osteoclasts, that remove 
bone and osteoblasts, that replace it (Hadjidakis DJ, 2006). In the normal adult skeleton bone 
formation occurs for the most part only where bone resorption has previously occurred. The 
complete remodeling cycle at each microscopic site takes about 3–6 months (Baron R, 2003). 
 
1.1.1. Bone cells 
 
 
Osteoblasts 
 
The osteoblast is the cell responsible for the production of the matrix constituents, the 
collagen and the ground substance, that is primarily composed of glycoproteins and 
proteoglycans. It originates from a local mesenchymal stem cell (bone marrow stromal stem 
cell or connective tissue mesenchymal stem cell) under the influence of local growth factors 
and differentiation factors such as fibroblast growth factors (FGFs), bone morphogenetic 
proteins (BMPs), and Wnt proteins, and requires the transcription factors Runx2 and Osterix. 
These precursors undergo proliferation and differentiate into preosteoblasts and then into 
mature osteoblasts. Osteoblasts do not appear or function individually but are always arranged 
in clusters along the bone surface. They are found lining the layer of bone matrix that they are 
producing, before it is calcified. Gap junctions are often found between the osteoblasts. Their 
plasma membrane is characteristically rich in alkaline phosphatase (ALP). Osteoblasts 
express steroid receptors for estrogens and vitamin D3 as well as several adhesion molecules 
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(integrins) and receptors for cytokines. They also express cytokines in their membrane, and in 
particular, colony-stimulating factor 1 (CSF-1) and RANKL, which can activate 
osteoclastogenesis in a local, paracrine manner. Osteoblasts also secrete osteoprotegerin, a 
decoy RANK receptor capable of inhibiting osteoclast formation (Baron R., 2003). 
Osteocalcin (OCN) expression is upregulated by vitamin D in human and in rat  osteoblasts 
(Mahonen A, 1990), but downregulated in mouse osteoblasts where it is increased by T3 
(Varga F, 2003). It is exclusively limited to cells of the osteoblastic lineage (Nakase T, 1994) 
and serves as a phenotypic marker for mature osteoblasts (Yeung F, 2002). 
Toward the end of the secreting period, the osteoblast becomes either a lining cell or an 
osteocyte. 
 
Osteocytes 
 
Osteocytes are found embedded deep within the bone in small osteocytic lacunae. They were 
originally bone-forming cells (osteoblasts), which became trapped in the bone matrix that they 
produced and later became calcified (Baron R, 2003). Until today, their function is not clearly 
defined, but they seem to play key roles in the response of bone to mechanical loading, and in 
the initiation of remodeling activity at specific sites within bone (Russel R.G, 2006). These 
cells have numerous and long cell processes rich in microfilaments, which are in contact with 
cell processes from other osteocytes or with processes from the cells lining the bone surface. 
These processes are organized during the formation of the matrix and before its calcification 
and form a network of thin canaliculi permeating the entire bone matrix. The morphology of 
younger and older osteocytes differs. A young osteocyte has most of the ultrastructural 
characteristics of the osteoblast from which it was derived, except that there has been a 
decrease in cell volume and in the importance of the organelles involved in protein synthesis. 
An older osteocyte, that is situated deeper within the calcified bone, shows these decreases 
further accentuated and there is an accumulation of glycogen in the cytoplasm. These cells 
have been shown to be able to synthesize new bone matrix at the surface of the osteocytic 
lacunae, which can subsequently calcify. The fate of the osteocytes is to be phagocytized and 
digested, together with the other components of bone, during osteoclastic bone resorption 
(Baron R, 2003). 
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Lining cells 
 
Lining cells originate from osteoblasts when their activity declines. They are thought to 
regulate the movement of phosphate and calcium into and out of the bone. They are assumed 
to play an important role in the coupling of bone resorption and formation. These cells also 
clean up the resorption pits after the osteoclast withdrawal (Everts V, 2002). 
 
Osteoclasts 
 
The osteoclast, a giant multinucleated cell that derives from cells in the 
mononuclear/phagocytic lineage, is the cell responsible for bone resorption. It develops from 
a mononucleated osteoclast-progenitor cell, that is in contact with osteoblasts and bone matrix 
and differentiates into a pre-osteoclast and then to a mature osteoclast (Klaushofer K, 1994). 
It is usually found in contact with a calcified bone surface and within a lacuna (Howship’s 
lacunae) that is the result of its own resorptive activity. The most prominent features of the 
osteoclast are the deep foldings of the plasma membrane in the area facing the bone matrix: 
the ruffled border in the center is surrounded by a ring of actin that serves to attach the cell to 
the bone surface. The basolateral plasma membrane is expressing RANK, the receptor for 
RANKL, and the macrophage-colony stimulating factor (M-CSF) receptor, both of which are 
responsible for osteoclast differentiation, as well as the calcitonin receptor, capable of 
inactivating rapidly the osteoclast (Baron R, 2003). These inactivated post-osteoclasts are 
characterized by the the appearance of vesicles with dark granular content (Klaushofer K, 
1989).  
 
 
1.2. Osteoblast-like tumour cell-lines 
 
Osteosarcoma (OS) is the most frequent malignant tumour of the bone and exhibits a peak in 
manifestation during the second and the third decade of life (Trieb K., 2003). The basic 
definition of osteosarcoma is the excessive production of pathological osteoid (Benayahu D, 
2001). Patients with metastatic disease at diagnosis have only a 20% survival rate (Walters 
DK, 2008). Primary chemotherapy for high-grade bone sarcomas often involves intensive, 
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multivalent regimens, and few secondary chemotherapy options are available to treat 
refractory or relapsed disease (Schuetze SM, 2007). 
A second type of cancer, that most commonly metastasizes to bone and causes significant 
mortality and morbidity in men with advanced disease, is prostate cancer. Recent autopsy data 
suggests that greater than 80% of men who die of prostate cancer have skeletal metastasis in 
the bone (Bubendorf  L, 2000; Hall CL, 2006). Despite its common occurrence, the molecular 
mechanisms responsible for prostate cancer growth, androgen-independent progression and 
acquisition of bone metastatic potential are poorly characterized.  
Studies show that bone matrix proteins like OCN and OPN are expressed at high levels in 
bone metastatic prostate cancer specimens (Brown LF, 1994; Curatolo C, 1992, Waltregny D, 
1998) and androgen-independent bone metastatic prostate cancer cell lines. There seems to be 
a remarkable parallelism in the temporal expression of bone matrix proteins by prostate 
cancer cells and osteoblasts (Yeung F, 2002).  
Tumour cells produce many factors including growth factors and cytokines (PTHrP, ET-1, 
BMPs, others...) that stimulate either ostoclast activity leading to osteolytic lesions or 
osteoblast activity generating osteosclerotic bone metastases (Peyruchaud O, 2007). 
Osteoclasts differentiate from bone marrow mononuclear cells through the action of receptor 
activator of NFkB ligand (RANKL). RANKL is expressed on mature osteoblasts and the 
receptor, RANK, is expressed on osteoclast precursors. The activity of RANKL is controlled 
by a secreted antagonist, osteoprotegerin (OPG), that prevents RANK/RANKL interactions 
and therefore osteoclastogenesis (Kostenuik PJ, 2005; Hall CL, 2006) The majority of cancers 
produce areas of osteolytic lesions when they metastasize to bone (Hall CL, 2006; Roodman  
GD, 2004). Prostate cancer is unique in that, in addition an osteolytic component, skeletal 
metastases are characterized by osteoblastic lesions (Keller E.T, 2001; Hall CL, 2006). 
Growth factors released from resorbed bone matrix or throughout osteoblastic bone formation 
sustain tumor growth. Therefore, bone metastases are the site of vicious cycles wherein tumor 
growth and bone metabolism sustain each other (Peyruchaud O, 2007) and where the 
metastasis of cancer cells to bone alters bone architecture and mineral homeostasis (Clines 
GA, 2008). 
In vitro studies of osteoblast behaviour utilize either osteoblast-like cells derived from animal 
and human bones (Beresford JN, 1984; Beresford JN, 1986) or osteogenic OS cell lines of 
animal or human origin (Rodan GA, 1988). Human OS cells can contribute to our 
understanding of osteoblast function because they initially represent clonal populations 
derived from specific stages of the osteoblast lineage (Clover J, 1994). 
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MG-63, human OS cells, are considered to show a number of features typical of an 
undifferentiated osteoblast phenotype. This includes the synthesis of collagen types 1 and 3, a 
low basal expression of ALP which is increased following 1,25-dihydroxyvitamin D3 (1,25 
(OH)2 D3) administration, and production of osteocalcin (OCN) in the presence of 1, 25 (OH)2 
D3 (Lajeunesse D, 1990; Franceschi RT, 1985). These cells have been used as an experimental 
model to study a variety of different osteoblast functions such as adhesion (Franceschi RT, 
1985; Dedhar S, 1987; Heino J, 1989), extracellular matrix synthesis (Bassols A, 1988, 
Franceschi RT, 1988), ALP activity (Boyan BD, 1989; Franceschi RT, 1985; Franchesci RT, 
1990) and OCN production (Lajeunesse D, 1990).  
Another human OS cell line is U-2 OS, which was isolated from a moderately differentiated 
sarcoma of the tibia of a young girl. A cell line of animal origin is UMR-106. This cell line is 
a clonal derivative of a transplantable rat OS that had been induced by injection of 
radiophosphorous. The cells are responsive to parathyroid-hormone (PTH), prostaglandins 
and bone resorbing steroids. U-2 OS and UMR-106 cells offer an epithelial phenotype 
(ATCC).  
To study prostate-carcinoma behaviour three human prostate cancer cell lines are commonly 
used. PC-3 cells are adherent cells that show an epithelial phenotype. They were initiated 
from a bone metastasis of a grade IV prostatic adenocarcinoma from a 62-year-old male 
Caucasian (ATCC). This cells share with mature osteoblasts the unique feature of 
synthesizing and depositing a large amount of OCN. It is considered a highly aggressive 
androgen-independent cell line which expresses neither androgen-receptor nor PSA and it 
does not require androgen for growth or survival. When injected intracardially in arythmic 
mouse, PC-3 cells have high propensity to metastasize to bone (Yeung F, 2002). DU-145, that 
show  also an epithelial phenotype, were isolated from a lesion in the brain of a 69 year old 
patient with metastatic carcinoma of the prostate and a 3 year history of lymphocytic 
leukemia. LNCaP clone FGC cells are adherent, single cells and loosely attached clusters with 
an epithelial phenotype. The cells were isolated from a needle aspiration biopsy of the left 
supraclavicular lymph node of a 50-year-old Caucasian male (ATCC). The LNCaP cell line is 
the only human prostate cell line established with functional androgen receptors and PSA 
(prostate specific antigen) expression (Horoszewicz  JS, 1983).  
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1.3. Lysyl Oxidase (LOX) 
 
Activated LOX was discovered by Pinnell and Martin in 1960 and it is the key enzyme that 
controls collagen and elastin maturation (Kagan HM, 1991). It is the most studied member of 
a family that includes other four structurally-related isoenzymes named LOX-like (LOXL)1, 
LOXL2, LOXL3 and LOXL4, whose specific substrates remain unclear (Molnar J, 2003). 
The gene encoding LOX has already been cloned, facilitating investigations of the regulation 
of expression of the enzyme in response to diverse stimuli and in numerous disease states. 
Transforming growth factor-β, platelet-derived growth factor, angiotensin 2, retinoic acid, 
fibroblast growth factor, altered serum conditions and stress are among the effectors or 
conditions that regulate LOX expression (Smith-Mungo LI, 1998). The LOX enzyme is 
localized within fibroblasts, chondrocytes, smooth muscle cells and in a variety of non-
fibroblastic cells, including endothelial, basal, biliary epithelial and glomerular epithelial cells 
(Iwasaki H, 1979). 
LOX catalyzes the oxidative deamination of peptidyl-lysine and hydroxylysine to peptidyl-a-
aminoadipic-d-semialdehyde. These aldehydes lead to a spontaneous condensation forming 
inter- and intra-chain cross-links into collagen and elastin (Kagan  HM 1991; Kagan HM, 
2003; Palamakumbura AH, 2004) . 
The process of cross-linking itself implies both, enzymatic catalysis, and a series of 
condensation reactions, to form intra and intermolecular cross-links. At present, seven major 
naturally occurring collagen cross-links have been established. They are dehydro-
dihydroxylysinonorleucine (deH-DHLNL), dehydro-histidinohydroxymerodesmosine (deH-
HHMD), histidinohydroxylysinonorleucine (HHL), pyridinoline (Pyr), deoxy-pyridinoline (d-
Pyr), pyrrole (Prl) and deoxy-pyrrole (d-Prl). 
The patterns of cross-linking and their molecular distributions vary from tissue to tissue. 
These patterns seem to be rather tissue - than collagen type specific, and probably are related to 
the physiological function of distinct tissues (Knott L, 1998). 
The lathyrogen ß-amino-propio-nitril (ßAPN) inhibits the collagen cross linking by blocking 
LOX and recently it was shown that ßAPN treatment decreased the two main cross-links Pyr 
and deH-DHLNL (Turecek C, 2008). Also the pro-atherogenic risk factor homocysteine 
downregulates LOX expression (Rodriguez C, 2008). In homocysteinemia increased serum 
levels of this amino-acid are suggested to inhibit LOX irreversibly, impairing subsequent 
cross-linking of collagen (Liu G, 1997).  
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The importance of normal cross-link formation for healthy tissue is displayed by a number of 
genetically inherited diseases. In Ehlers-Danlos syndrome (EDS) type VI, which is 
characterized by connective tissue dysfunctions such as kyphoskoliosis or ruptures of the eye 
and the aorta, the level of hydroxylation is reduced to 17% of normal bone, due to a 
deficiency in LOX enzyme activity (Acil Y, 1995). 
Conversely, overhydroxylation, as a consequence of retarded triple helix formation, can be 
observed in different forms of osteogenesis imperfecta (Lehmann HW, 1995).  
It has traditionally been assumed that the role of LOX is restricted to the oxidation of peptidyl 
lysine in extracellular collagen and elastin substrates, resulting in the deposition of insoluble 
fibrous deposits of these proteins (Smith-Mungo LI, 1998) but in the last few years it was 
found out that the LOX propeptide, which is released during extracellular proteolytic 
processing of pro-lysyl oxidase  possesses anti-cancer activity (Palamakumbura AH, 2004). 
The RAS gene family encodes small GTPase proteins that transduce signals that promote 
growh and survival from membrane-bound receptor tyrosine kinases (Downward J, 2003;  
Wu M., 2007). Mutated Ras proteins have been detected in 25% of lung cancers and in up to 
85% of pancreatic cancers (Almoguera C, 1988; Hruban RH, 1993; Wu M, 2007). The 
findings that LOX is downregulated in these ras-transformed cells and in many tumour cell 
lines (Palamakumbura AH, 2004; Contente S, 1990) as well as in human cancers (Kuivaniemi 
H, 1986; Krzyzosiak WJ, 1992; Hämäläinen ER, 1995; Ren C, 1998) show that LOX has a 
second, well-defined function. Spontaneous reversion of cancers or induced phenotypic 
reversion is accompanied by increased LOX expression (Hajnal A, 1993) and the suggested 
function as a tumour suppressor was directly shown by transfection of antisense LOX, which 
triggers transformation of normal rat fibroblasts and reversion of stable phenotypic revertants 
of ras- transformed NIH3T3. This tumour suppressor function was recently attributed to the 
18-kDa propeptide (Ren C, 1998; Palamakumbura AH, 2004), which is processed from the 
secreted 50 kDa proenzyme by the procollagen C-proteinase BMP-1 (bone morphogenic 
protein-1) (Kessler E, 1996). The larger fission product is the active enzyme responsible for 
the initiation of the cross-links. Reduced LOX mRNA levels were found in experimental and 
human prostate cancer (Ren C,1998) and recently, by means of methylation-sensitive 
representational difference analysis, LOX silencing was found by DNA-methylation in human 
gastric, colon, lung, and ovarian cancer cells (Kaneda A, 2004). More recently it was found 
that in human lung and pancreatic cancer cells that carry N-ras and K-ras mutations, 
respectively, the tumour suppressing part of LOX strongly inhibits ras signalling and NF-κB 
activity, and Bcl-2 was identified as an essential target of propeptide–mediated inhibition of 
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the transformed phenotype (Wu M, 2007). Furthermore it was shown that the LOX propeptide 
functions as a tumour suppressor in breast cancer cells both in vitro and in vivo, and reverts 
the invasive phenotype of Her-2/neu-driven breast cancer (Min C, 2007). All these findings 
support the relationship between LOX and tumourigenicity.  
 
1.4. Osteocalcin (OCN) 
 
OCN, a phenotypic marker for mature osteoblasts (Yeung F, 2002), is the main non-
collagenous protein of the bone matrix and its expression is highly regulated by many local 
and humoral factors. It possesses several features of a hormone and is a cell-specific molecule 
that is synthetisized as a prepro-molecule and secreted in the general circulation (Hauschka  
PV, 1989; Price PA, 1989; Lee NK, 2007).  
Because of their exquisite cell-specific expression OCN genes have been intensively studied 
to identify osteoblast-specific transcription factors and to define molecular bases of bone 
physiology (Harada S, 2003). Clinically OCN is routinely used as a serum marker for bone 
formation (Delmas PD, 1986) and it also has an importance as a marker for malignancies such 
as prostate carcinoma. Patients with bone metastases due to prostate cancer have higher levels 
of OCN and ALP than people that are lymph-node negative. So, bone turnover markers, 
including OCN represent a new diagnostic tool in prostate cancer (Hegele A, 2007). OCN 
also plays a role as a marker for leukemia and it was shown that OCN is expressed in 
neoplastic stem cells in hematological malignancies  (Wihlidal P, 2006).  
OCN expression is regulated by 1,25 D3 but this regulation depends strictly on the species. In 
human and rat osteoblasts OCN is upregulated by 1,25 D3 (Mahonen A, 1990) but this 
observation could not be found in mouse osteoblasts, where OCN is upregulated by 
triiodothyronine (T3) (Varga F, 2003). OCN-deficient mice have a higher bone mass and 
improved bone functional quality (Ducy P, 1996-1), and histomorphometric studies done 
before and after ovariectomy showed that the absence of OCN leads to an increase in bone 
formation in mice without impairing bone resorption (Ducy P, 1996-2).  
Recently, it was shown that OCN also plays a key role in the interaction between energy and 
bone metabolism. Mice that lack the protein tyrosine phosphatase OST-PTP are 
hypoglycemic and are protected from obesity and glucose intolerance because of an increase 
in beta-cell proliferation, insulin secretion, and insulin sensitivity. In contrast, mice that lack 
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the osteoblast-secreted molecule OCN display decreased beta-cell proliferation, glucose 
intolerance, and insulin resistance (Lee NK, 2007). 
 
1.5. Runx2 
 
Runx2 is a member of the Runx family of nuclear transcription factors and was first termed 
PEBP2α, CBFα, AML or OSF (Ito Y, 1999; Adya N, 2000; Karsenty G, 2000). The Runx 
family consists of three members (Runx1, Runx2 and Runx3) and one characteristic feature is 
the runt domain, a highly conserved DNA binding and protein-protein interaction motif 
(Kamachi Y, 1990).  
The members of the Runx family localize in the nuclei to punctuate foci that are involved in 
transcriptional control and associate with the subnuclear scaffold designated as the nuclear 
matrix (Zeng C, 1997; Zeng C, 1998; Tang L, 1999; Stein GS, 2000). Runx1 and Runx2 
contain a C-terminal nuclear –matrix-targeting signal (NMTS) that is necessary for directing 
these proteins to intranuclear foci (Bidwell JP, 1994; Zeng C, 1997; Stein GS, 2000). Runx2 
is expressed in the early pluripotent mesenchymal cell prior to expression of the osteoblast 
phenotype and increases during osteoblast differentiation (Komori  T, 1997; Banerjee C, 
2001). The role of Runx2 as a master regulator of osteoblast differentiation has been proved 
by the targeted deletion of the Runx2 gene in mice (Otto F, 1997; Komori T, 2002). Runx2-/- 
mice die shortly after birth (Otto F, 1997) and few, if any, differentiated osteoblasts can be 
found in these mice (Komori T, 2000). The protein has long been regarded as a bone-specific 
transcription factor, where it regulates bone specific and related genes, but a few years ago it 
has also been reported in metastatic mammary epithelial cells but not in normal human 
mammary cells. It was proposed that this expression of Runx2 is ectopic and that the 
expression in these metastatic cancer cells may explain the osteoblastic phenotype of human 
breast cancer cells (Barnes GL, 2003), as well as prostate cancer cells (Yeung F, 2002) that 
metatstasized to the bone (Barnes GL, 2003). But later it was found out that the protein is also 
expressed in mammary epithelial cell lines derived from normal mammary gland, non 
metatstatic mammary cancer cells and primary mammary epithelial cells (Inman CK, 2003). 
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1.6. The influence of drugs on osteoblastic-like cancer cells 
 
1.6.1. The effects of suramin on human and rat OS cells 
 
OS is the most frequent malignant tumour of the bone and affects people in the second and the 
third decade of life (Benayahu D, 2001). The survival rate for patients with metastatic disease 
lies only at about a 20% (Walters DK, 2008). 
Suramin is a polysulfonated naphthylurea compound that has been widely used for the 
treatment of trypanosomiasis (sleeping sickness) and onchocerciasis (Hawking F, 1978). It 
possesses six sulfonic groups that are attached directly to aromatic rings. The molecule was 
originally synthesized in 1916 based on the observation that trypan red and trypan blue 
exhibited trypanocidal activity (La Rocca RV, 1990-2). Its anticancer activity was later 
identified and suramin has been introduced into clinical trials for various forms of cancer (La 
Rocca RV, 1990-1; La Rocca RV, 1990-2; Garcia-Schürmann JM, 1999; Small EJ, 2000; 
Song S, 2001). This agent has shown some promise in phase 2 clinical trials in the 
management of hormone-refractory human prostate cancer (Thalmann GN, 1996) and high 
doses of suramin inhibit growth of malignant histiocytomas in vitro (Abdiu A, 1999). 
Tumour cell differentiation depends on growth factor autocrine loops (Franchi A, 1998; 
Girnita L, 2000) that play an important role in malignant bone tumour development (Mason 
IJ, 1994; Yamaguchi K, 2006) Fibroblast growth factor (FGF)-2 autocrine loop controls 
human OS phenotyping and differentiation (Bodo M, 2002). 
Suramin forms strong complexes with many proteins, including growth factors and their 
receptors. Recently it was shown that FGF-1 binds to suramin with high affinity in the 
nanomolar range which prevents interaction with its receptors (Kathir KM, 2006). Suramin 
triggers enterocyte-like differentiation of the human colic adenocarcinoma cell clone HT29-
D4 and IGF-I secreted by the cells themselves, stimulates proliferation of HT29-D4 cells via 
an autocrine mechanism. Blockade of this stimulation by suramin or by a specific monoclonal 
antibody inhibits cell growth, glucose uptake and triggers the process of enterocytic 
differentiation (Baghdiguian S, 1992). 
As already discussed above, blocking of the autocrine loop of growth factors seems not to be 
the sole task of suramin on OS cells (Benini S, 2001). This blocking could explain the up 
regulation of ALP and OCN (Bodo M, 2002) and down regulation of cell multiplication, 
which could be influenced by decrease of Telomerase activity (Trieb K, 2003). The substance 
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drastically upregulated LOX expression and induced phenotype reversion of transformed 
NIH3T3 that, as already mentioned above, is mediated by the LOX propeptide domain 
(Palamakumbura AH, 2004). 
 
 
1.6.2. The effects of valproate and 5`-aza- 2-`deoxycytidine (5-AZAC) on 
human prostate cancer cell-lines  
 
Prostate cancer is an increasing prevalent health problem among males (Emami KH, 2007). 
Despite its common occurrence, the molecular mechanisms responsible for prostate cancer 
growth, androgen-independent progression and acquisition of bone metastatic potential are 
poorly characterized. This kind of cancer most commonly metastasizes to lymph node and 
bone and causes significant mortality and morbidity in men with advanced disease (Yeung F, 
2002). Studies show that bone matrix proteins like OCN and OPN are expressed at high levels 
in bone metastatic prostate cancer specimens (Curatolo C, 1992; Brown LF, 1994; Waltregny 
D, 1998) and androgen-independent bone metastatic prostate cancer cell lines. There seems to 
be a remarkable parallelism in the temporal expression of bone matrix proteins by prostate 
cancer cells and osteoblasts (Yeung F, 2002). 
Metastatic prostate cancer is generally treated by homone therapy (Huggins JP, 1994) and 
when prostate cancer progresses to an androgen-independent state, non of the proposed 
therapeutic regimens has provided evidence for objective tumor response or a significant 
survival benefit (Thalmann GN, 1996). However, the clinical manifestation of this disease 
varies greatly, from indolent tumors, requiring little or no treatment, to those aggressive 
cancers which require radical therapies.  
Prostate cancer, like all other cancers, develops and progresses as a consequence of an 
accumulation of genetic changes (Bott SR, 2005). Recently, common variants on human 
chromosome 8q24 were found to be associated with prostate cancer risk (Yeager M, 2007). 
Epigenetic alterations, mainly promoter hypermethylation of cancer-related genes, are found 
in nearly all tumours and in prostate cancer they were suggested as biomarkers (Costa VL, 
2007). Epigenetic events are defined as alterations in gene expression without changes in the 
DNA coding sequence, that are heritable through cell division (Waddington CH, 1969).  
DNA methylation and histone modification are two mechanisms that are integral to epigenetic 
transcriptional control. DNA methylation describes the addition of a methyl group to the 
cytosine residue of a CpG dinucleotide by DNA methyltransferases (DNMTs) (Walton TJ, 
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2008). It is found in the genomes of different organisms including both prokaryotes and 
eukaryotes. In prokaryotes, DNA methylation occurs on cytosine and adenine bases (Wilson 
GG, 1991) but in multicellular eukaryotes methylation seems to be confined to cytosine bases 
and is associated with a repressed chromatin state and the inhibition of gene expression (Bird 
AP, 1999). DNA methyltransferases (DNMTs) are important regulators of gene transcription 
and because they play a role in carcinogenesis they have been intensively studied in the last 
few years (Yu N, 2008). The methyltransferases DNMT3a and DNMT3b are mainly 
responsible for introducing cytosine methylation at unmethylated CpG sites, whereas the 
methyltransferase DNMT1 copies pre-existing methylation patterns onto the new DNA strand 
during DNA replication. The DNA methyltransferase, DNMT2, shows weak DNA 
methyltransferase activity in vitro (Hermann A, 2003), but targeted deletion of the DNMT2 
gene in embryonic stem cells causes no detectable effect on global DNA methylation. So, this 
enzyme seems to have little involvement in setting DNA methylation patterns (Okano M, 
1998). DNMT3L is a DNMT-related protein and does not contain DNA methyltransferase 
activity, but physically associates with DNMT3a and DNMT3b and modulates their catalytic 
activity (Suetake I, 2004). 
In the mammalian genome, methylation takes place only at cytosine bases that are located 5′ 
to a guanosine in a CpG dinucleotide. This dinucleotide is actually underrepresented in much 
of the genome, but short regions of 0.5–4 kb in length, known as CpG islands (Bird A, 2002), 
that occur in the promoter region of approximately 60% of genes (Gardiner-Garden M, 1987), 
are rich in CpG content (Bird A, 2002). Most CpG islands are found in the proximal promoter 
regions of almost half of the genes in the mammalian genome and are, generally, 
unmethylated in normal cells. In cancer, however, the hypermethylation of these promoter 
regions is now the most well-categorized epigenetic change to occur in tumours. It is found in 
virtually every type of human neoplasm and is associated with the inappropriate 
transcriptional silencing of genes (Baylin SB, 2000). 
As already mentioned above, inappropriate DNA methylation is thought to be important in the 
development of a majority of cancers, including prostate cancers (Walton TJ, 2008) and 
today, over 30 genes have been shown to be epigenetically silenced by hypermethylation in 
prostate cancer, including genes controlling cell cycle progression, tumor cell invasion, DNA 
repair, and hormonal response (Li LC, 2005). Estrogen receptor β (ERβ) is one such hormonal 
response gene known to be hypermethylated in prostate cancer (Li LC, 2000) and 
upregulation of ERβ following co-treatment  may sensitize prostate cancer cells to subsequent 
treatment with conventional estrogens (Walton TJ, 2008). ERβ contains a CpG island within 
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its promoter (Li LC, 2000) and has been shown to be re-expressed in prostate cancer cell-lines 
treated with DNMT inhibitors such as 5`-aza- 2`-deoxycytidine (5-AZAC) (Lau KM, 2000; 
(Sasaki M, 2002). 
Another mechanism of epigenetic transcriptional control results from histone modifications. 
Histones form the core around which double-stranded DNA is coiled to form a nucleosome. 
They are subject to a number of post-tranlational protein modifications, such as acetylation, 
methylation, phosphorylation and ubiquination (Zhang Y, 2001). Histone acetylation is 
associated with transcription activation, whereas deacetylation is associated with 
transcriptional silencing. Dysregulated epigenetic control of gene expression by histone 
modification is thought to be important in the development of a number of cancers, including 
prostate cancer (Li LC, 2005). Both processes, histone modification and DNA methylation are 
linked, although they are two independent processes (Li E, 2002). DNMT`s, for example, 
recruit histone-deacetylases (HDACs) leading to histone deacetylation by removing the acetyl 
group from the histone (Jamaluddin MD, 2007) and transcriptional repression (Fuks F, 2001; 
Robertson KD, 2000). And methylated DNA binding proteins can recruit HDAC`s to the site 
of DNA methylation (Nan X, 1998; Jones PA, 2002). Histone deacetylation leads to 
chromatin condensation and inhibits the access of regulatory proteins to the promoter 
(Jamaluddin MD, 2007). It has been shown that the combination of HDAC and DNMT 
inhibitors induces apoptosis, differentiation and/or cell growth arrest in human lung, breast, 
thoracic, leukemia and colon cancer cell lines (Zhu WG, 2003). In prostate cancer, a number 
of studies have reported reductions in cell proliferation and apoptosis in cell lines treated with 
HDAC inhibitors alone (Thelen P, 2004; Fronsdal K, 2005), but little is known about the 
effects of combined treatment. 
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1.7. Aims of the work 
 
Osteosarcoma and prostate cancer are two types of cancer that target different groups of 
people. As osteosarcoma is the most common malignant primary bone tumor in children and 
adolescents, prostate cancer is one of the most diagnosed and potentially devastating cancers 
in men, throughout the world.  
One fact that both types of cancer have in common is that they both affect bone because 
osteosarcoma itself develops in bone and prostate cancer cells metastasize to bone and lymph 
nodes and cause significant mortality and morbidity in men with advanced disease. 
Today, many therapeutical options are available to treat osteosarcoma and prostate cancer. 
Current optimal treatment for osteosarcoma consists of multi-agent chemotherapy and 
aggressive surgical resection of all sites of disease involvement. The current national and 
international cooperative trial for patients with newly diagnosed osteosarcoma builds upon the 
backbone of cisplatin, doxorubicin, and methotrexate. Suramin has not yet been tried in 
patients with osteosarcoma and little is known about its in vitro effects on osteosarcoma cells. 
The clinical manifestation of prostate cancer varies from indolent tumours, requiring little or 
no treatment to aggressive cancers which require radical therapies.  
Epigenetic alterations are defined as alterations in gene expression without changes in the 
DNA coding sequence and in cancer promoter hypermethylation of cancer-related genes can 
be found. DNA methylation and histone modification are two mechanisms that are integral to 
epigenetic transcriptional control. A number of studies have reported reductions in cell 
proliferation and apoptosis in cancer cell lines treated with histone-deacetylases (HDACs ) 
inhibitors, but little is known about the effects of combination therapy of DNA 
methyltransferases (DNMTs) and HDACs inhibitors in cancer cell lines. 
Lysyl Oxidase (LOX) is an enzyme that is responsible for the collagen cross-linking in bone 
and it was found that the LOX propeptide, which is released during extracellular proteolytic 
processing of pro-lysyl oxidase, has some anti-cancer activity. 
Aim of this thesis was to study the effects of Suramin, the DNMT inhibitor 5´-aza-2´-
deoxycytidine and the HDAC inhibitor valproate on different osteoblast-associated tumour 
cell lines, taking into special consideration the effects on osteoblastic differentiation and LOX 
expression, as LOX is downregulated in human cancers. Therefore, osteoblast–specific genes 
were analysed to show if the three mentioned drugs cause a differentiation of the cells.  
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2.2. The effects of valproate and 5`-aza- 2`-deoxycytidine on human 
prostate cancer cell-lines 
 
2.2.1 Material and Methods 
 
Cell culture 
Human PC-3, DU 145 and LNCaP cells were purchased from American Type Culture 
Collection. PC-3 cells (CRL-1435) were grown in DMEM (Dulbecco`s minimal essential 
medium; Sigma)/F-12K medium containing 10% FCS and 10 μg/ml gentamycin. DU 145 
(HTB-81) and LNCaP (CRL-1740) cells were grown in αMEM (α-minimum essential 
medium; Biochrom, Germany) supplemented with 10% FCS (Biochrom, Germany) and 10 
μg/ml gentamycin. 
 
Cell multiplication 
Experiments were performed to determine the optimal seeding concentration of the cells. 
Therefore, different cell numbers (250, 500, 1000, 2000, 4000, 8000, 16 000 and 32 000 cells 
/cm2) were seeded into individual wells in a 48-well plate to a total volume of 500 μl. 
Each experiment was performed in quadruplicate with additional wells filled with media 
alone. On day 5 the media were removed and the cells were washed twice with PBS and 
frozen at −20°C. During subsequent thawing, 500 μl Hoechst 33258 solution (10 μg/ ml, 10 
mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.1 mM EDTA) were added to each well. The 
amount of DNA was quantitated by measuring the fluorescence in a multiwell fluorometer 
(excitation 355/emission 460; Tecan). DNA was estimated using a standard curve prepared 
from calf thymus DNA (Roche).  
To analyse if the DNMT inhibitor 5-AZAC and the HDAC inhibitor valproate have an effect 
on cell multiplication on the described cell lines 8000 cells/cm2  were seeded in 24-well plates 
and treated either with 5 uM 5-AZAC or 1 mM valproate or with both drugs. Untreated cells 
served as a control. On day 1, 2, 3 and 7 the amount of DNA was quantitated as described 
above.  
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RNA isolation and reverse transcription 
Cells were plated in 50 cm2 plates at a density of  8,000 cells/cm2. After 24 hours of culture, 
cells were treated either with 5 uM 5-AZAC or 1 mM valproate or with both drugs. Untreated 
cells served as a control. On day 1 and 7 total RNA was isolated using TRIzol reagent 
(Invitrogen) according to the manufacturer`s protocol. RNA was cleaned using RNeasy Mini 
Kit (QIAGEN). The first-strand cDNA was synthesized from 1 μg of total RNA by means of 
AMV reverse transcriptase (Invitrogen). Analyses were performed by real time PCR. 
 
LOX, Runx2 and OPG mRNA expression 
After mRNA isolation and reverse transcription was done, expression analyses were 
performed by real time PCR using TaqMan Gene Expression System (Applied Biosystems). 
TaqMan GAPDH probes were used as a housekeeping gene, amplified in the same tube. An 
amplification program (as suggested by Applied Biosystems) with 59°C annealing 
temperature was used for 60 cycles. For quantification of the RT-PCR a linear amplification 
was assumed. All PCR’s were performed as triplicate  
 
OCN mRNA expression 
Epression analyses were performed by real time PCR using SYBR Green (Roche 
Diagnostics). Specific primers for the coding sequence of human OCN were as follows: upper 
primer, 5`-CAT GAG AGC CCT CAC A -3` and lower primer 5`-AGA GCG ACA CCC 
TAG AC -3`. mRNA expression of GAPDH was used for normalization. RTQ-PCR was 
carried out using a Rotor-Gene real-time system (Corbett Research) using 2.5 µM of specific 
primers: 15 seconds denaturation at 95°C temperature, followed by 45 cycles with 58°C 
annealing temperature for 15 seconds and 72°C extension temperature for 20 seconds. PCR 
cycles were followed by the melting curves from 72°C to 95°C with a temperature transition 
rate of 0.5°C/s. For quantification of the RT-PCR a linear amplification was assumed. All 
PCR’s were performed as triplicate. 
 
Statistical analysis 
Statistical significance was tested by t-test or ANOVA (post hoc: Bonferroni) using Prism 4.0 
(GraphPad Software Inc., CA, USA). 
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2.2.2. Results and Discussion 
 
Effects of 5-AZAC and valproate on cell multiplication 
Firstly, careful optimization experiments were performed to determine the optimal seeding 
concentration of the three human prostate cancer cell lines DU-145, PC-3 and LNCaP. As 
shown in Fig.1, a seeding concentration of about 8000 cells/cm2 for all cell lines was the 
optimal concentration that was associated with unrestricted cell proliferation. After 5 days of 
culture the amount of DNA in the three cell lines shows that the cell multiplication of DU-145 
cells was higher than those of PC-3 and LNCaP cells. Therefore, DU-145 cells earlier reached 
confluence than the other cell lines.   
Fig. 2 shows the visual appearance of the three different cell lines after 7 days of single-agent 
treatment with 5-AZAC or valproate, and co-treated cells. In concordance with the 
observations on cell multiplication, as described above, all cultures of DU-145 either 
untreated or treated with 5-AZAC or valproate, or with both drugs nearly reached confluence 
(Fig. 2A), but valproate seemed to reduce cell proliferation more than 5-AZAC or co-treated 
cells. 
Untreated PC-3 cells (Fig.2B) were confluent and even cells treated with 5-AZAC or 
valproate alone nearly reached confluence. In this cell line 5-AZAC seemed to be more potent 
in reducing cell multiplication and co-treatment resulted in a further reduction (Fig. 2B). 
LNCaP cells (Fig. 2C) were not confluent but formed a loose network of cells with contacts 
(untreated cells) or appeared in small groups (co-treated cells). Following 5-AZAC treatment 
cell proliferation was reduced and similar appearance was seen following valproate treatment. 
Combined treatment resulted in a further reduction in cell proliferation. 
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Fig.1: Effects of seeding concentration on DNA amount of DU-145 (A), PC-3 (B) and LNCaP 
(C) cells after 5 days of culture. Hoechst dye was added (10 μg/ml) and the fluorescence of 
the incorporated dye was measured at 360/460 nm.  
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A 
 
untreated cells        treatment with 5-AZAC 
 
 
treatment with valproate       co-treated cells 
 
Fig. 2A: 
Visual appearance of DU-145 cells after 7 days of single-agent treatment with 5-AZAC and 
valproate, or with both drugs. Untreated, single-treated and even co-treated DU-145 cells  
nearly reached confluence, but valproate seemed to reduce cell proliferation more than 5-
AZAC. 
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treatment with valproate      co-treated cells 
 
Fig. 2B: 
Visual appearance of PC-3 cells cells after 7 days of single-agent treatment with 5-AZAC and 
valproate, or with both drugs. Untreated PC-3 cells were confluent and even cells treated with 
5-AZAC or valproate alone nearly reached confluence. In this cell line 5-AZAC seemed to be 
more potent in reducing cell proliferation and co-treatment resulted in a further reduction. 
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treatment with valproate      co-treated cells 
 
Fig. 2C: 
Visual appearance of LnCaP cells after 7 days of single-agent treatment with 5-AZAC and 
valproate, or with both drugs. Cells were not confluent but formed a loose network of cells 
with contacts (untreated cells) or appeared in small groups (co-treated cells). Following 5-
AZAC treatment cell proliferation was reduced with a higher proportion of dead cells. Similar 
appearance was seen following valproate treatment and combined treatment resulted in a 
further reduction in cell proliferation. 
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Although, in our studies, all treatments significantly reduced cell multiplication in DU-145 
cells, the absolute DNA content was higher than in both other cell lines (Fig. 3A, control). 
Moreover, the DNA contents of the treated cultures were still conspicuously different to the 
other cell lines, explaining the obvious difference in the confluence (compare Fig. 3A, 3B,  
3C). In the LNCaP cell lines valproate was more effective in the regulation of cell 
multiplication and treatment with both drugs further decreased cell number of  7 day old 
cultures. 
There have been many approaches to understand the mechanism by which DNMT and HDAC 
inhibitors could cause these reductions in cell multiplication. HDAC inhibitors, like valproate, 
induce cell cycle arrest, differentiation and/or apoptosis of tumour cell lines in vitro 
(Schroeder TM, 2005) and it has been reported that the HDAC inhibitor valproate alone 
reduces cell proliferation in human PC-3 and LNCaP prostate cancer cells (Iacopino F, 2008). 
One approach is the re-activation of tumour suppressor genes by DNMT inhibitors and 
HDAC inhibitors. P16 INK4a is a major tumour suppressor implicated in a wide variety of 
human cancers (Ruas M, 1998; Sherr CK, 2000; Park YB, 2002). Inactivation of p16INK4a by 
promoter hypermethylation is common in a variety of human cancers, including osteosarcoma 
(Herman JG, 1995; Park YB, 2002). Another mechanism is DNA-methylation dependent 
downregulation of genes like P14ARF that associates and stabilizes tumour suppressor genes 
like p53 (Liggett WH, 1996; Esteller M., 2000; Park YB, 2002). It was shown that the p14ARF 
promoter was methylated in the osteosarcoma cell line U2OS and thus, osteosarcoma can be 
one of the tumor types showing methylation-dependent inactivation of the p14ARF promoter 
(Park YB, 2002). So, DNMT inhibitors like 5-AZAC and HDAC inhibitors like valproate 
could re-express the tumour suppressor genes p16 INK4a and p14ARF in human prostate cancer 
cell lines, which leads to reduced cell multiplication in these cells. 
Another mechanism was demonstrated in HUVEC´s, where homocysteine, a possible 
inhibitor of DNMT`s, inhibits promoter-specific methylation. As a consequence, it was 
demonstrated that a repressor binds instead of methyl-binding-proteins downregulating 
transcription of cyclin A and proliferation (Jamaluddin MD, 2007). 
Recently, it was shown that in renal cell carcinoma HDAC inhibitors strongly influence gene 
expression of cell-cycle regulating proteins, in particular, CDK2, cyclin B, cyclin D3, Rb and 
p21 (Jones J, 2008). The latter was shown to regulate proliferation of colon cancer cells. 
Downregulation of HDAC by siRNA resulted in downregulation of p21 and proliferation 
(Wilson AJ, 2008). This supports our findings that inhibition of HDAC by valproate 
downregulated cell multiplication. 
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Fig. 3: Effects of 5-AZAC and valproate on DNA amount of human DU-145 (A), PC-3 (B) 
and LNCaP (C) cells after 7 days of treatment either with 5 uM 5-AZAC, 1 mM valproate or 
with both drugs. Hoechst dye was added (10 μg/ml) and the fluorescence of the incorporated 
dye was measured at 360/460nm.Bars represent means ± SD.  
*** P≤0.001 (5-AZAC, valproate and co-treatment vs control); ### P≤0.001 (valproate, co-
treatment vs 5-AZAC); + P≤0.05 (valproate vs 5-AZAC) 
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LOX mRNA expression 
Diminished levels of LOX can be found in cancer cell lines as well as in transformed cell 
lines (Kuivaniemi H, 1986; Contente S, 1990; Ren C, 1998; Palamakumbura AH, 2003). 
Recently it has been shown that in human osteosarcoma cell lines LOX is increased by 
suramin and this drug also reduced cell multiplication in these cells (Buchinger B, 2008). In 
human primary and metastatic prostate cancer LOX expression is markedly reduced compared 
with benign glandular epithelium of the prostate and loss of LOX expression is associated 
with prostate cancer progression (Ren C, 1998). Therefore we were interested in the effects of 
5-AZAC and valproate on LOX expression in the three human prostate cancer cell lines and if 
the gene is re-expressed by this drugs. 
In LNCaP cells no LOX mRNA expression could be determined (data not shown), going 
confirm with the report that in lymph node metastases reduced LOX mRNA can be found 
compared to primary prostate cancer cells (Ren C, 1998).  
Human GAPDH-normalized gene expression for LOX is shown in Fig. 4 and Fig. 5.  
Co-treatment increased LOX expression already on the first day of treatment in DU-145 cells 
(Fig. 4A). Both, 5-AZAC and valproate showed a trend towards upregulation but the 
difference was not statistically significant. Surprisingly, after 7 days of culture, the LOX 
expression in the controls increased to the level as found after 1 day of co-treatment that did 
not change during further culture time. The same expression was found with 5-AZAC and 
valproate after 7 days of treatment (Fig. 4B). At that time point all cultures reached 
confluence.  
In the cell line of prostate metastasis from bone (PC-3) valproate significantly increased LOX 
expression after 1 day of treatment compared to controls (Fig. 5A). 5-AZAC did not increase 
LOX expression on the first day of treatment in these cell lines, but, as in DU-145 cells, a 
trend could be observed. Combined treatment resulted in a strong increase of LOX expression 
after this culture time. After 7 days of culture, as found in DU-145 cells controls strongly 
expressed LOX (Fig. 5B). This expression was about twice as high as all treatments and 
strongly significant. Both, 5-AZAC and valproate increased LOX expression compared to that 
found on day 1 and similarly expression of the valproate treated cells was higher than that of 
5-AZAC. Compared to 1 day expression, 7 days co-treatment did not further increase LOX 
expression. 
Fig. 2 suggests that for basal as well as for single-agent treatment confluence plays an 
important role in LOX expression. In co-treated PC-3 cells that did not reach confluence after 
7 days of culture expression of LOX seems to be regulated by the drugs. 
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Taking these findings together valproate stimulated the expression of LOX in the two prostate 
cancer cell lines DU 145 and PC-3. 5-AZAC also showed some increase in LOX expression, 
but data were not significant. Combined treatment had an additional effect on LOX 
expression, already after 1 day of culture.  
Analyses of the methylation status of the LOX promoter demonstrated that PC-3 cells show 
decrease of methylation during the culture period. This seemingly correlates with LOX 
expression. Treatment with 5-AZAC did not influence methylation status of the promoter. 
Both, valproate and combined treatment prevented methylation of CpG´s in the LOX 
promoter (Thaler R, unpublished results). This suggests, that valproate itself can upregulate 
LOX expression possibly by increase of histone acetylation. 
Controversially 5-AZAC increased demethylation of promoter CpG´s of LOX in DU-145 
cells already after 1 day treatment which did not change during further culture time. Similarly 
to PC-3 cells after 7 days of culture demethylation status reached a maximum with all 
treatments (Thaler R, unpublished results). Again, this suggests that methylation status 
depends on cell density or culture time and correlates with LOX expression. Further 
experiments are in progress to clarify this topic. 
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Fig. 4: Relative LOX-expression in DU-145 cells after 1 day (A) and 7 days (B) of treatment. 
The total RNA amount of cells treated either with 5 uM 5-AZAC, 1 mM valproate or with 
both drugs and the control group was isolated using TRIzol reagent. Analysis of the specific 
cDNA was performed with a real time PCR. 
Bars represent means ± SD. *** P≤0.001 (control, 5-AZAC, valproate vs co-treatment)  
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Fig. 5: Relative LOX-expression in PC-3 cells after 1 day (A) and 7 days (B) of treatment. 
The total RNA amount of cells treated either with 5 uM 5-AZAC, 1 mM valproate or with 
both drugs and the control group was isolated using TRIzol reagent. Analysis of the specific 
cDNA was performed with a real time PCR  
Bars represent means ± SD. *** P≤0.001 (control, 5-AZAC, valproate vs co-treatment) 
#P≤0.05 (valproate vs control); +++ P≤0.001 (5-AZAC, valproate, co-treatment vs control) 
●●●P≤0.001 (valproate vs 5-AZAC); ♦♦P≤0.01 (co-treatment vs 5-AZAC) 
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Runx2 mRNA expression 
Runx2 belongs to the runt domain transcription factor family (Ogawa E 1993; Yeung F, 
2002). and plays a major role in osteoblast differentiation, maturation and bone formation 
(Komori T, 1997; Yeung F, 2002). This skeletal transcription factor is aberrantly expressed at 
high levels in breast and prostate cancers and cells that aggressively metastasize to the bone 
and was shown to regulate early metastatic events in these cancer types (Pratap J, 2006).  
Prostate cancer bone metastases express numerous proteins associated with bone cells. 
Specific transcription factors, including Runx2 regulate the expression of many bone-related 
factors in osteoblasts and the expression of Runx2 may be the molecular switch that is 
associated with expression of various bone-specific factors in prostate cancer (Brubaker KD, 
2003) 
Runx2 is expressed in the aggressive androgen-independent prostate cancer cell lines DU 145 
and PC-3. In the latter cell line, Runx2 binds to the OSE2 site in the hOC promoter and 
regulates the transcription of OCN (Yeung F, 2002). Recent studies have identified several 
co-repressor proteins that bind to Runx2 to regulate gene expression. Binding sites for both 
histone acetylases and HDAC´s were identified on this protein (Westendorff JJ, 2006).  
Our results show that valproate increased Runx2 expression in DU 145 already on the first 
day of treatment compared to controls (Fig.6 A). Combined treatment resulted in a further 
increase of Runx2 expression which was about three times as high as with valproate treatment 
and 6 times as high as 5-AZAC and control. 
After 7 days of treatment, in confluent DU-145 cells, (Fig. 6B) all cultures reached the level 
of the co-treated cells found at day 1.  
In 7 day old PC-3 cultures (Fig. 7B) Runx2 expression did not change in untreated cells 
compared to day one (Fig. 7A), while all other treatments increased mRNA expression of 
Runx2 significantly. Valproate increased mRNA expression about 7 times, while both 5-
AZAC and co-treatment stimulated only 4 times. The difference between 5-AZAC and 
valproate was statistically significant. 
LNCaP cells are OCN negative and do not express Runx2 (Yeung F, 2002). In concordance 
with this, in our studies no Runx2 expression could be detected (data not shown). 
Taken together our data suggest that the HDAC inhibitor valproate has an effect on Runx2 
expression in DU-145 and PC-3 cells. Recently it was described that trichostatin, an HDAC 
inhibitor like valproate increased, osteogenic factors like ALP, Runx2 and osteopontin. It was 
suggested that Twist-1, a key regulator of mesenchymal differentiation, inhibits BMP-
signalling by HDAC1 recruiting to SMAD, and prevents differentiation (Hayashi M. 2007). 
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This could be a mechanism how valproate increased Runx2 expression and osteoblastic 
differentiation. 
The results show, that in both cell lines co-treatment increased Runx2 expression. One main 
difference between the cell lines was that in DU 145 cells confluence seemed to regulate 
Runx2 expression; this was not the case in PC-3 bone metastatic cells, where control did not 
change during the culture period. However, all treatments increased Runx2 expression after 7 
days of treatment, indicating that they promote osteoblastic differentiation. 
Surprisingly, in this study, no OCN expression, neither in DU 145, nor in PC-3 cells could be 
detected. OCN expression requires an intact extracellular bone-like matrix. Unfavorable 
culture conditions for proper matrix formation in the cultures could be a reasonable 
explanation (Fig. 2). As expected, in LNCaP neither OCN, nor Runx2 was properly expressed 
(Yeung F, 2002).  
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Fig. 6: Relative Runx2-expression in DU-145 cells after 1 day (A) and 7 days (B) of 
treatment. The total RNA amount of cells treated either with 5 uM 5-AZAC, 1 mM valproate 
or with both drugs and the control group was isolated using TRIzol reagent. Analysis of the 
specific cDNA was performed with a real time PCR.  
Bars represent means ± SD.*** P≤0.001 (control, 5-AZAC, valproate vs co-treatment); 
#P≤0.05 (valproate vs control)  
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Fig. 7: Relative Runx2-expression in PC-3 cells after 1 day (A) and 7 days (B) of treatment. 
The total RNA amount of cells treated either with 5 uM 5-AZAC, 1 mM valproate or with 
both drugs and the control group was isolated using TRIzol reagent. Analysis of the specific 
cDNA was performed with a real time PCR .Bars represent means ± SD. *** P≤0.001 
(control, 5-AZAC, valproate vs co-treatment)#P≤0.05 (5-AZAC vs control);+++P≤0.001 
(valproate vs control); ●●P≤0.01 (co-treatment vs control); ♦ P≤0.05 (valproate vs 5-AZAC) 
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Bone metastases of prostate cancer can result in either lytic, that means bone resorbing, or in 
osteoblastic, that means bone forming metastases (Peyruchaud O, 2007). Under physiological 
conditions the ratio between RANKL and OPG determines whether bone is formed or 
resorbed (Hamdy A, 2008). Therefore there is great interest whether in bone metastase the 
ratio of both genes directs bone formation or resorption. As the PC-3 cell line is a human 
prostate cancer cell metastases from the bone we were interested in the RANKL/OPG ratio to 
determine how the cells react under the treatment of 5-AZAC and DNMT inhibitors.  
Results show that in confluent PC-3 cells 5-AZAC and valproate increased OPG expression 
significantly compaired to controls (Fig. 8). Surprisingly, no RANKL expression could be 
found. These observations, however, let us suggest that the cell line was established from a 
metastases with bone-forming properties.    
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Fig.8: Relative OPG-expression in PC-3 cells after 7 days of treatment. The total RNA 
amount of cells treated either with 5 uM 5-AZAC, 1 mM valproate or with both drugs and the 
control group was isolated using TRIzol reagent. Analysis of the specific cDNA was 
performed with a real time PCR .Bars represent means ± SD. ** P≤0.01 (5-AZAC vs control) 
##P≤0.01 (valproate vs control);+++P≤0.001 (co-treatment t vs control); ●●●P≤0.001 (5-AZAC 
vs co-treatment); ♦♦♦ P≤0.001 (valproate vs co-treatment ) 
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3. Epilogue 
 
Osteosarcoma and prostate cancer are two types of cancer that both affect bone because 
osteosarcoma itself develops in bone and prostate cancer cells metastasize to bone, lymph 
nodes and other organs and cause significant mortality and morbidity in men with advanced 
disease (Yeung F, 2002). Autopsy data suggest that greater than 80% of men who die of 
prostate cancer have skeletal metastasis, specifically in the marrow containing trabecular bone 
of the pelvis, femur, or vertebral bodies (Bubendorf L, 2000, Hall CL, 2006). 
Tumour cell lines afford the opportunity to investigate effects of drugs on metabolic 
processes. Three drugs, all in use for tumour treatment, were studied. These drugs act on 
different levels of gene transcription: Suramin is known to affect biochemical signal-
transduction, valproate, an inhibitor of histone-deacetylases and 5-AZAC, an inhibitor of 
DNMT`s, affect chromatin, one on the level of histone modification, the other directly on the 
DNA methylation. Their influence on cell multiplication and differentiation as indicators of 
normalization of tumour cells were investigated.   
Suramin is known to interrupt the autocrine loop of signal transduction between expressed 
growth factors and their receptors (Hosang M, 1979). This could explain our finding of 
downregulation of cell multiplication, confirming previous data (Trieb K, 2003). 
In addition, suramin increased ALP activity, OCN, COL1A1 and OPN expression in these 
cell lines. These results clearly demonstrate that suramin increased the differentiation status of 
the tumour cells.  
A central point of our investigation was the effects of these drugs on LOX expression, as the 
N-terminal part of the protein is known to posses tumour suppressor (anti-cancer) activity 
(Kagan HM, 2003; Palamakumbura AH, 2004). This interesting protein, secreted as a 
precursor, is cleaved by procollagen C-proteinase (BMP-1), yielding a tumour suppressor part 
and an active enzyme that is responsible for collagen cross-linking (Kessler E, 1996). As a 
matter of fact suramin significantly and dose-dependently increased LOX mRNA expression 
and lead us to the speculation that this gene could be responsible for the found effects on 
proliferation and differentiation in OS cell lines.  
Next we studied whether the “epigenetic drugs”, (HDAC and DNMT inhibitors), also 
influence LOX expression in tumour cell lines. For this purpose this drugs were used alone or 
in combination to treat three prostate cancer cell lines that were isolated from bone (PC-3), 
lymph-node (LNCaP) and brain (DU-145) metastases. While in LNCaP cells no LOX 
expression could be detected in the other two cell lines combined treatment with HDAC and 
 48
DNMT inhibitors resulted in a strong upregulation of LOX mRNA expression. Surprisingly 
and different to the results found with suramin in OS cells, after 7 days of culture the LOX 
expression increased strong and significantly, indicating that culture age or confluence effect 
LOX expression in the same way. 
The fact that the expression of the osteoblast-specific transcription factor Runx2 goes in line 
with LOX expression in PC-3 and DU-145 cells suggests that LOX could also influence the 
differentiation to an osteoblastic phenotype like suramin.  
These data let us hypothesize that these drugs could effect tumour development in a positive 
way. One could further speculate that a formally dedifferentiated phenotype found in bone 
metastases tends to ameliorate.  
The findings that LOX expression parallels the improvement of cancer are supported by many 
in vitro and in vivo studies (Palamakumbura AH , 2004; Wu M, 2007;  Min C, 2007).   
These results clearly demonstrate that reversion the differentiation of cancer cells could be 
influenced at the biochemical as well as at the epigenetic level and recommend to strive 
elucidating the molecular mechanisms of this processes. 
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  treatment 
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6. Index of abbreviations 
 
ALP  Alkaline Phosphatase 
5-AZAC  5`aza 2`deoxycytidin  
ßAPN ß -amino-propio-nitril  
BMP  Bone morphogenic protein 
DNMT  DNA methyltransferase 
ERβ  Estrogen receptor β  
FGF-2 Fibroblast growth factor-2 
HDAC histone deacetylase 
IGF  Insulin-like growth factor 
LOX  Lysyl Oxidase 
OCN  Osteocalcin 
OPG  Osteoprotegerin 
OPN  Osteopontin 
OS  Osteosarcoma  
PTH  Parathyroid hormone 
RANK Receptor activator of NFkB 
RANKL Receptor activator of NFkB ligand 
TGF–β Tumour growth factor β 
T3  triiodthyroxin  
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